---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-068974"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2023-12-08T23:59:59+00:00"
generated_at: "2026-06-07T15:38:38.600100+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# FDA approves first CRISPR therapy, CASGEVY; Vertex to pay CRSP $200M milestone

## Summary
- FDA approved CASGEVY (exagamglogene autotemcel) for sickle cell disease in patients 12+ with recurrent vaso-occlusive crises.
- Vertex set wholesale acquisition cost at $2.2 million for CASGEVY in the U.S.
- Approval triggered Vertex's $200 million milestone payment to CRISPR Therapeutics under the joint development agreement.
- This is the first-ever FDA approval of a CRISPR-based gene-editing therapy.

## SEC filing metadata
- accession: 0000950170-23-068974
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2023-12-08T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017023068974/0000950170-23-068974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017023068974/crsp-20231208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-068974
- JSON: https://secwatch.observer/filing/0000950170-23-068974.json
- Plain text: https://secwatch.observer/filing/0000950170-23-068974.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.